PO-524 MT4-MMP, EGFR and Rb expressions are predictive biomarkers of response to erlotinib-palbociclib combination in TNBC

• Published in: ESMO open Vol. 3; no. Suppl 2; p. A436
• Main Authors: Foidart, P, Yip, C, Radermacher, J, Collignon, J, Coibion, M, Blacher, S, Marangoni, E, Sounni, NE, Noël, A, Jerusalem, G
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.07.2018

IntroductionTriple negative breast cancer (TNBC) comprises heterogeneous agressive tumours. The standard treatment relies entirely on chemotherapy. While EGFR is expressed in 50%–75% of TNBC, clinical trials with erlotinib or cetuximab fail to show clinical benefit. Recently, we demonstrated that EG...